Currently, there have been no Food and Drug Administration (FDA)-approved drugs targeting AKT1 and PPARG pathways specifically for regulating lipid metabolism in anti-obesity treatment. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.